You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022292

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

NDA 022292 describes APTIVUS, which is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the APTIVUS profile page.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tipranavir profile page.
Summary for 022292
Applicant:Boehringer Ingelheim
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 022292
Generic Entry Date for 022292*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022292
Mechanism of ActionHIV Protease Inhibitors
Suppliers and Packaging for NDA: 022292
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
APTIVUS tipranavir SOLUTION;ORAL 022292 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0002 0597-0002-01 1 BOTTLE, GLASS in 1 CARTON (0597-0002-01) > 95 mL in 1 BOTTLE, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength100MG/ML
Approval Date:Jun 23, 2008TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Dec 22, 2019Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:Apr 29, 2020Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.